Log in

NASDAQ:SNGXSoligenix Stock Price, Forecast & News

$2.10
+0.29 (+16.02 %)
(As of 05/25/2020 03:26 PM ET)
Add
Compare
Today's Range
$1.84
Now: $2.10
$2.19
50-Day Range
$1.36
MA: $1.51
$1.70
52-Week Range
$0.65
Now: $2.10
$3.54
Volume2.84 million shs
Average Volume1.14 million shs
Market Capitalization$55.82 million
P/E RatioN/A
Dividend YieldN/A
Beta1.1
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials for the treatment of vaccine against ricin toxin poisoning; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of emerging and/or antibiotic-resistant infectious diseases. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.
Read More
Soligenix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNGX
CUSIPN/A
Phone609-538-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.60 million
Book Value$0.07 per share

Profitability

Net Income$-9,360,000.00
Net Margins-351.69%

Miscellaneous

Employees14
Market Cap$55.82 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive SNGX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.

Soligenix (NASDAQ:SNGX) Frequently Asked Questions

How has Soligenix's stock been impacted by COVID-19 (Coronavirus)?

Soligenix's stock was trading at $2.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SNGX stock has decreased by 17.3% and is now trading at $2.10. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Soligenix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Soligenix.

When is Soligenix's next earnings date?

Soligenix is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Soligenix.

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) posted its quarterly earnings data on Friday, May, 15th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.21. The biopharmaceutical company had revenue of $0.90 million for the quarter. Soligenix had a negative net margin of 351.69% and a negative return on equity of 542.83%. View Soligenix's earnings history.

What price target have analysts set for SNGX?

1 Wall Street analysts have issued 1-year price targets for Soligenix's stock. Their forecasts range from $4.00 to $4.00. On average, they expect Soligenix's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 90.5% from the stock's current price. View analysts' price targets for Soligenix.

Has Soligenix been receiving favorable news coverage?

News headlines about SNGX stock have trended somewhat positive on Monday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Soligenix earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutSoligenix.

Who are some of Soligenix's key competitors?

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Trevena (TRVN), vTv Therapeutics (VTVT), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), ImmunoGen (IMGN), Nokia Oyj (NOK) and Verastem (VSTM).

Who are Soligenix's key executives?

Soligenix's management team includes the following people:
  • Dr. Christopher J. Schaber, Chairman, CEO & Pres (Age 53)
  • Ms. Karen R. Krumeich, CFO, Sr. VP & Corp. Sec. (Age 65)
  • Dr. Oreola Donini, Sr. VP & Chief Scientific Officer (Age 47)
  • Dr. Richard C. Straube, Sr. VP & Chief Medical Officer (Age 67)
  • Mr. Richard L. Dunning, Exec. Officer (Age 73)

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

Who are Soligenix's major shareholders?

Soligenix's stock is owned by many different retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (0.43%), First Wilshire Securities Management Inc. (0.39%), S&T Bank PA (0.15%), WMS Partners LLC (0.10%) and Savant Capital LLC (0.06%). Company insiders that own Soligenix stock include Christopher J Schaber, Diane L Parks, Jerome B Zeldis and Mark E Pearson. View institutional ownership trends for Soligenix.

Which major investors are buying Soligenix stock?

SNGX stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, First Wilshire Securities Management Inc., S&T Bank PA, WMS Partners LLC, and Savant Capital LLC. Company insiders that have bought Soligenix stock in the last two years include Christopher J Schaber, Diane L Parks, Jerome B Zeldis, and Mark E Pearson. View insider buying and selling activity for Soligenix.

How do I buy shares of Soligenix?

Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $2.10.

How big of a company is Soligenix?

Soligenix has a market capitalization of $55.82 million and generates $4.60 million in revenue each year. The biopharmaceutical company earns $-9,360,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Soligenix employs 14 workers across the globe.

What is Soligenix's official website?

The official website for Soligenix is www.soligenix.com.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.